Clin2
NCT07536165Possibly a fitNot yet recruiting

Late-window IV tenecteplase for acute ischemic stroke

StrokeAcute Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This registry tracks how well tenecteplase (a clot-busting medication) works when given more than 4.5 hours after a stroke starts. Researchers want to learn if treating strokes this late can still help patients recover.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
3,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older
  • You have been diagnosed with an acute ischemic stroke (a clot blocking blood flow to your brain)
  • More than 4.5 hours have passed since you last felt normal, even if you didn't see the stroke happen
  • You received intravenous tenecteplase (a clot-busting drug injected into your vein)
  • You can provide written informed consent or have an authorized representative do so

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07536074Not yet recruiting
Study of clot-busting treatment for stroke beyond standard time

This study tracks patients who receive IV thrombolysis (a clot-busting medication injected into the vein) for acute ischemic stroke more than 4.5 hours after their stroke started. Researchers want to learn whether this extended-window treatment can still help patients recover when given outside the typical time window.

Guangzhou, Guangdong
NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT07092709Recruiting· Phase 3
Tenecteplase for stroke patients who recently took blood thinners

This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.

Guangzhou, Guangdong
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires
NCT06954155Recruiting· Phase 3
Tenecteplase for stroke treatment 24-72 hours after symptoms start

This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.

Beijing
NCT07094763Recruiting
Tenecteplase for posterior stroke 4.5-24 hours after onset

This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.

Hefei

Hear when a new Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.